Replies to post #607355 on NorthWest Biotherapeutics Inc (NWBO)

[Know-Fear]

ATLn, I’ll chime in with $.02 starting with old post where the highlighted section may align with your thinking.

Know-Fear
Re: flipper44 post# 558564
Wednesday, January 11, 2023 1:16:04 PM
Post# of 607373
Agreed, sometimes my sarcasm doesn’t translate well on the message board. Hopefully, and to quote another poster this is potentially “next level stuff”, perhaps along the lines of what I was alluding to in post 547857.
A couple other quick thoughts as I don’t have much time. The Flaskworks patents* provide more protection IMO than the patent they got on Direct back in October 2021. That stated I sense that using L would be the preferred method in practice medically. As removing as much tumor burden as possible as well as ensuring a greater antigen uptake will provide better efficacy. And any synergies with CI’s will be at dose levels more tolerable.

* Suspect some of the Flaskworks patents are defensive in nature to block alternate paths.

Agree likely some “art” involved in administering Direct injections to attain/ensure efficacy.
Also on the direct patent the prosecution was lengthy. The time and changes made some think the claims were diminished. I think the attained what they needed (ex an I made this points at the time)

Coming in for landing try add more when time permits

[dstock07734]

ATL, Doc,

Thanks you both for the great posts.

We saw Owain James only had half his tumor removed and he only had three doses of DCVax-L. His tumor has been shrinking even four months after the last shot. I was wondering if this would lower the importance of pushing DCVax-Direct. If doctor can inject the Direct into tumor, certainly a certain amount of tumor tissue can be extracted to make DCVax-L.